4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price
FDMTStock
$12.14+20.32%52W
Market Cap$670.66M
P/E—
PEG Ratio—
Div yield—
Beta2.92
FDMT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)15.77%
Price vs S&P 500 (4W)-19.02%
VGM Score73.19
FDMT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.02 | -$1.04 | -2.29%(-$0.02) | |
| Q1 2026 | -$1.00 | -$1.01 | -1.45%(-$0.01) | |
| Q4 2025 | -$0.53 | $0.43 | +181.44%(+$0.96) | |
| Q3 2025 | -$0.98 | -$1.01 | -2.79%(-$0.03) | |
| Q2 2025 | -$0.69 | -$0.98 | -41.37%(-$0.29) |
FDMT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.12
4.12
4.11
4.11
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
FDMT4D Molecular Therapeutics, Inc. Common Stock | C | A | B | 7.3x | 278712.1% | — | — | $12.14 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics is a clinical-stage gene therapy company developing novel treatments using evolved AAV vectors across three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company's pipeline includes multiple product candidates targeting retinal diseases, heart conditions, and pulmonary disorders, leveraging its proprietary vector technology designed for targeted delivery and efficacy. With programs spanning intravitreal, intravenous, and aerosol administration routes, 4D is advancing a diversified approach to gene therapy development.